Market Place
News Type
Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme. 
X
Details:
The Phase 2 interim results of VAT00002 showed 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old) and across all doses, with acceptable tolerability and with no safety concerns.
Lead Product(s): SARS-CoV-2 Recombinant Protein Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: VAT00002
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
DDF Summit 2022 US
Not Confirmed
Contact SupplierDetails:
The new Phase 2 trial is a randomized, double-blind, multi-center dose finding study conducted in adults aged 18 years of age and older to evaluate the safety, reactogenicity, and immunogenicity of two Adjuvanted recombinant protein-based COVID-19 vaccine given 21 days apart.
Lead Product(s): Adjuvanted recombinant protein-based COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
DDF Summit 2022 US
Not Confirmed
Contact SupplierDetails:
The study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, the main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in the world that specifically targets this protein.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
OVX836, targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Valneva is planning to use the proceeds to support its contribution to the planned Phase 3 development program for Lyme disease vaccine candidate VLA15. Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.
Lead Product(s): VLA15
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA15
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 23, 2022
Details:
Osivax will apply the funds to prepare OVX836 for a Phase 2b field efficacy clinical trial to assess its efficacy against a broad range of circulating strains. OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Funding June 23, 2022
Details:
VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A of Borrelia burgdorferi.
Lead Product(s): VLA15
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA15
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 20, 2022
Details:
OVX836 is Osivax’ T-cell based influenza candidate developed using the company’s proprietary oligoDOM® nanoparticle technology platform and designed to produce immune responses against the nucleoprotein (NP), a highly conserved internal antigen across flu strains.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Under the collaboration, NIAID will provide its self-assembling ferritin nanoparticles that serve as scaffolding to display multiple copies of HA protein, expressed on the surface of influenza viruses, to Osivax for in vivo preclinical studies in combination with OVX836.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2022
Details:
Study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in world that specifically targets this protein.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
